Compare Eli Lilly And Co (LLY) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Micron Technology, Inc. — how do they compare? Eli Lilly And Co trades at $1,159.69 (market cap $1.02T), while Micron Technology, Inc. trades at $977.61 (market cap $977.44B). The key difference: Eli Lilly And Co and Micron Technology, Inc. are close in size by market cap, and Eli Lilly And Co pays the higher dividend (0.6%). Which is the better fit depends on your goals.
| LLY | MU | |
|---|---|---|
Market Cap | $1.02T | $977.44B |
Sector | Health | Technology |
52-Week High | $1.24K | $1.21K |
52-Week Low | $625.65 | $104.88 |
Enterprise Value | $1.06T | $957.80B |
Dividend Yield | 0.6% | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Micron (MU) trades at $862.32, down 1.57% with a bearish technical signal, though it remains 30% below its 52-week high. The company reported strong Q3 2025 earnings of $4.78 EPS, beating expectations, with revenue surging to $37.38 billion. Analyst consensus is strongly bullish with an 81.43% buy rating and a $1,550 price target. Recent news highlights memory chip demand driven by AI, though sector-wide bear market concerns persist.
Outlook remains positive due to robust AI-driven memory demand and earnings beats, but risks include cyclical industry volatility and competitive pressures. The stock offers growth potential if it maintains execution amid high expectations, yet investors should monitor sector sentiment and guidance updates for sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
